Cargando…
PB2035: CAMMA 3: A MULTICENTER PHASE IB TRIAL EVALUATING THE SAFETY, PHARMACOKINETICS, AND ACTIVITY OF SUBCUTANEOUS CEVOSTAMAB MONOTHERAPY IN PATIENTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA
| Autores principales: | , , , , , , , , , , , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Lippincott Williams & Wilkins
2022
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9429653/ http://dx.doi.org/10.1097/01.HS9.0000850972.76878.85 |
| _version_ | 1784779523404857344 |
|---|---|
| author | Delimpasi, S. Quach, H. Cavo, M. Ho, P. J. Lee, C. H.-S. Santoro, A. Schots, R. Vlummens, P. Yoon, D. H. Yoon, S.-S. Santos, C. D. Samineni, D. Huang, J. Wehrman, K. Patil, U. Sheikh, S. Dimopoulos, M. A. |
| author_facet | Delimpasi, S. Quach, H. Cavo, M. Ho, P. J. Lee, C. H.-S. Santoro, A. Schots, R. Vlummens, P. Yoon, D. H. Yoon, S.-S. Santos, C. D. Samineni, D. Huang, J. Wehrman, K. Patil, U. Sheikh, S. Dimopoulos, M. A. |
| author_sort | Delimpasi, S. |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-9429653 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2022 |
| publisher | Lippincott Williams & Wilkins |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-94296532022-08-31 PB2035: CAMMA 3: A MULTICENTER PHASE IB TRIAL EVALUATING THE SAFETY, PHARMACOKINETICS, AND ACTIVITY OF SUBCUTANEOUS CEVOSTAMAB MONOTHERAPY IN PATIENTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA Delimpasi, S. Quach, H. Cavo, M. Ho, P. J. Lee, C. H.-S. Santoro, A. Schots, R. Vlummens, P. Yoon, D. H. Yoon, S.-S. Santos, C. D. Samineni, D. Huang, J. Wehrman, K. Patil, U. Sheikh, S. Dimopoulos, M. A. Hemasphere Publication Only Lippincott Williams & Wilkins 2022-06-23 /pmc/articles/PMC9429653/ http://dx.doi.org/10.1097/01.HS9.0000850972.76878.85 Text en Copyright © 2022 The Author(s). Published by Wolters Kluwer Health, Inc. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access Abstract Book distributed under the Attribution-NonCommercial-NoDerivs (CC BY-NC-ND) (https://creativecommons.org/licenses/by-nc-nd/4.0/) which allows third parties to download the articles and share them with others as long as they credit the author and the Abstract Book, but they cannot change the content in any way or use them commercially. |
| spellingShingle | Publication Only Delimpasi, S. Quach, H. Cavo, M. Ho, P. J. Lee, C. H.-S. Santoro, A. Schots, R. Vlummens, P. Yoon, D. H. Yoon, S.-S. Santos, C. D. Samineni, D. Huang, J. Wehrman, K. Patil, U. Sheikh, S. Dimopoulos, M. A. PB2035: CAMMA 3: A MULTICENTER PHASE IB TRIAL EVALUATING THE SAFETY, PHARMACOKINETICS, AND ACTIVITY OF SUBCUTANEOUS CEVOSTAMAB MONOTHERAPY IN PATIENTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA |
| title | PB2035: CAMMA 3: A MULTICENTER PHASE IB TRIAL EVALUATING THE SAFETY, PHARMACOKINETICS, AND ACTIVITY OF SUBCUTANEOUS CEVOSTAMAB MONOTHERAPY IN PATIENTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA |
| title_full | PB2035: CAMMA 3: A MULTICENTER PHASE IB TRIAL EVALUATING THE SAFETY, PHARMACOKINETICS, AND ACTIVITY OF SUBCUTANEOUS CEVOSTAMAB MONOTHERAPY IN PATIENTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA |
| title_fullStr | PB2035: CAMMA 3: A MULTICENTER PHASE IB TRIAL EVALUATING THE SAFETY, PHARMACOKINETICS, AND ACTIVITY OF SUBCUTANEOUS CEVOSTAMAB MONOTHERAPY IN PATIENTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA |
| title_full_unstemmed | PB2035: CAMMA 3: A MULTICENTER PHASE IB TRIAL EVALUATING THE SAFETY, PHARMACOKINETICS, AND ACTIVITY OF SUBCUTANEOUS CEVOSTAMAB MONOTHERAPY IN PATIENTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA |
| title_short | PB2035: CAMMA 3: A MULTICENTER PHASE IB TRIAL EVALUATING THE SAFETY, PHARMACOKINETICS, AND ACTIVITY OF SUBCUTANEOUS CEVOSTAMAB MONOTHERAPY IN PATIENTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA |
| title_sort | pb2035: camma 3: a multicenter phase ib trial evaluating the safety, pharmacokinetics, and activity of subcutaneous cevostamab monotherapy in patients with relapsed or refractory multiple myeloma |
| topic | Publication Only |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9429653/ http://dx.doi.org/10.1097/01.HS9.0000850972.76878.85 |
| work_keys_str_mv | AT delimpasis pb2035camma3amulticenterphaseibtrialevaluatingthesafetypharmacokineticsandactivityofsubcutaneouscevostamabmonotherapyinpatientswithrelapsedorrefractorymultiplemyeloma AT quachh pb2035camma3amulticenterphaseibtrialevaluatingthesafetypharmacokineticsandactivityofsubcutaneouscevostamabmonotherapyinpatientswithrelapsedorrefractorymultiplemyeloma AT cavom pb2035camma3amulticenterphaseibtrialevaluatingthesafetypharmacokineticsandactivityofsubcutaneouscevostamabmonotherapyinpatientswithrelapsedorrefractorymultiplemyeloma AT hopj pb2035camma3amulticenterphaseibtrialevaluatingthesafetypharmacokineticsandactivityofsubcutaneouscevostamabmonotherapyinpatientswithrelapsedorrefractorymultiplemyeloma AT leechs pb2035camma3amulticenterphaseibtrialevaluatingthesafetypharmacokineticsandactivityofsubcutaneouscevostamabmonotherapyinpatientswithrelapsedorrefractorymultiplemyeloma AT santoroa pb2035camma3amulticenterphaseibtrialevaluatingthesafetypharmacokineticsandactivityofsubcutaneouscevostamabmonotherapyinpatientswithrelapsedorrefractorymultiplemyeloma AT schotsr pb2035camma3amulticenterphaseibtrialevaluatingthesafetypharmacokineticsandactivityofsubcutaneouscevostamabmonotherapyinpatientswithrelapsedorrefractorymultiplemyeloma AT vlummensp pb2035camma3amulticenterphaseibtrialevaluatingthesafetypharmacokineticsandactivityofsubcutaneouscevostamabmonotherapyinpatientswithrelapsedorrefractorymultiplemyeloma AT yoondh pb2035camma3amulticenterphaseibtrialevaluatingthesafetypharmacokineticsandactivityofsubcutaneouscevostamabmonotherapyinpatientswithrelapsedorrefractorymultiplemyeloma AT yoonss pb2035camma3amulticenterphaseibtrialevaluatingthesafetypharmacokineticsandactivityofsubcutaneouscevostamabmonotherapyinpatientswithrelapsedorrefractorymultiplemyeloma AT santoscd pb2035camma3amulticenterphaseibtrialevaluatingthesafetypharmacokineticsandactivityofsubcutaneouscevostamabmonotherapyinpatientswithrelapsedorrefractorymultiplemyeloma AT saminenid pb2035camma3amulticenterphaseibtrialevaluatingthesafetypharmacokineticsandactivityofsubcutaneouscevostamabmonotherapyinpatientswithrelapsedorrefractorymultiplemyeloma AT huangj pb2035camma3amulticenterphaseibtrialevaluatingthesafetypharmacokineticsandactivityofsubcutaneouscevostamabmonotherapyinpatientswithrelapsedorrefractorymultiplemyeloma AT wehrmank pb2035camma3amulticenterphaseibtrialevaluatingthesafetypharmacokineticsandactivityofsubcutaneouscevostamabmonotherapyinpatientswithrelapsedorrefractorymultiplemyeloma AT patilu pb2035camma3amulticenterphaseibtrialevaluatingthesafetypharmacokineticsandactivityofsubcutaneouscevostamabmonotherapyinpatientswithrelapsedorrefractorymultiplemyeloma AT sheikhs pb2035camma3amulticenterphaseibtrialevaluatingthesafetypharmacokineticsandactivityofsubcutaneouscevostamabmonotherapyinpatientswithrelapsedorrefractorymultiplemyeloma AT dimopoulosma pb2035camma3amulticenterphaseibtrialevaluatingthesafetypharmacokineticsandactivityofsubcutaneouscevostamabmonotherapyinpatientswithrelapsedorrefractorymultiplemyeloma |